U.S. Markets open in 5 hrs 59 mins

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
15.92+0.12 (+0.76%)
At close: 04:00PM EST
16.00 +0.08 (+0.50%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.80
Bid0.00 x 4000
Ask0.00 x 1200
Day's Range15.77 - 15.94
52 Week Range12.28 - 16.30
Avg. Volume2,839,673
Market Cap49.496B
Beta (5Y Monthly)0.75
PE Ratio (TTM)30.27
EPS (TTM)0.53
Earnings DateN/A
Forward Dividend & Yield0.73 (5.60%)
Ex-Dividend DateMar 30, 2022
1y Target Est17.63
  • Business Wire

    U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older

    OSAKA, Japan & CAMBRIDGE, Mass., February 03, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of TAKHZYRO® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to <12 years of age.1 Prior to today’s approval, the only approved routine prophylaxis treatment options for children 6 to <12 years of age requir

  • Insider Monkey

    Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2023 Earnings Call Transcript

    Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2023 Earnings Call Transcript February 2, 2023 Christopher O’Reilly: Thank you for taking time out of your very busy schedule to join us for the FY €˜22 Q3 Earnings Announcement by Takeda. My name is O’Reilly, Head of IR. I’ll be the master of ceremony today. Before starting, I’d […]

  • Benzinga

    Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged

    Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported a 13% drop in operating earnings to ¥401.9 billion for the nine months ending December. However, it reaffirmed its profit outlook for FY22. Operating profit for Q3 increased 21% (1% on constant currency) to ¥329.5 billion. Related: HUTCHMED Out Licenses Fruquintinib To Takeda Outside China. In December, Takeda agreed to shell out $4 billion to Nimbus Therapeutics for an allosteric tyrosine kinase 2 inhibitor for multiple autoimmune diseases. Reve